SCHEMBL24373361

SCHEMBL24373361

COC(=O)c1cc2ccc(Br)cc2[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.51
NR4A2 P43354 1/20 0.50
EGFR P00533 1/20 0.47
KDM4E B2RXH2 4/20 0.46
GAA P10253 2/20 0.46
GLA P06280 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
POLB P06746 1/20 0.43
DYRK1A Q13627 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
LMNA P02545 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29478893 1.00 CHEK1 (0.51) CHEK1NR4A2EGFRKDM4EGAA
SCHEMBL19512086 0.85 ALDH1A1 (0.55) KDM4EGAAALDH1A1TSHRHSD17B10
SCHEMBL30237524 0.85 ALDH1A1 (0.55) KDM4EGAAALDH1A1TSHRHSD17B10
SCHEMBL10330638 0.84 KDM4E (0.61) NR4A2KDM4EGAAGLAALDH1A1
SCHEMBL31423177 0.82 DAO (0.56) KDM4EGAAGLAALDH1A1TSHR
SCHEMBL25424978 0.82 GAA (0.50) KDM4EGAAGLAALDH1A1TSHR
SCHEMBL30529291 0.82 GAA (0.50) KDM4EGAAGLAALDH1A1TSHR
SCHEMBL24373426 0.82 KDM4E (0.59) NR4A2KDM4EGAAALDH1A1TSHR
SCHEMBL10330650 0.82 DAO (0.56) CHEK1NR4A2EGFRKDM4EGAA
SCHEMBL2898509 0.81 KDM4E (0.50) KDM4EGAAGLAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 US disclosed
WO-2022083569-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC CHEK1 256/4885NR4A2 2061/4885EGFR 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.